Recent News

04/29/2016
Appendix 4C Quarterly Report Quarter Ended 31 March 2016
Read More

03/23/2016
GI Dynamics Announces the Appointment of Medical Device Industry Veteran Scott Schorer as President ...
Read More

03/15/2016
GI Dynamics Announces Top-Line Results from U.S. Pivotal Clinical Trial of EndoBarrier® Therapy (th...
Read More


The GI Dynamics’ EndoBarrier® Gastrointestinal Liner System is used for the treatment of obese type 2 diabetes with BMI ≥ 30 kg/m2, or obese patients with BMI ≥ 30 kg/m2 with ≥ 1 comorbidities, or obese patients with BMI >35 kg/m2.
The liner is indicated for maximum implant duration of 12 months.
EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE